NasdaqGS:INCYBiotechs
Will Tafasitamab’s Phase 3 Win and Rare‑Disease Advances Change Incyte's (INCY) Narrative?
In recent days, Mirum Pharmaceuticals and Incyte reported pivotal data and regulatory progress across several programmes, including positive Phase 3 frontMIND results for tafasitamab in high‑risk DLBCL/HGBL, pivotal Phase 2 PROGRESS data and FDA Priority Review for zilurgisertib in FOP, and updated Phase 1 data for INCA033989 in MF and ET.
Taken together, these updates highlight Incyte’s attempt to build a broader oncology and rare‑disease portfolio that is less dependent on any single...